Peninsula Asset Management Inc Lowers stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : Peninsula Asset Management Inc reduced its stake in C R Bard Inc by 1.1% during the most recent quarter end. The investment management company now holds a total of 18,375 shares of C R Bard Inc which is valued at $4 Million after selling 205 shares in C R Bard Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.C R Bard Inc makes up approximately 3.38% of Peninsula Asset Management Inc’s portfolio.

Other Hedge Funds, Including , Massachusetts Financial Services Co boosted its stake in BCR in the latest quarter, The investment management firm added 18,587 additional shares and now holds a total of 665,519 shares of C R Bard Inc which is valued at $145.5 Million. C R Bard Inc makes up approx 0.08% of Massachusetts Financial Services Co’s portfolio.Amalgamated Bank boosted its stake in BCR in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 2,945 shares of C R Bard Inc which is valued at $643,924. C R Bard Inc makes up approx 0.06% of Amalgamated Bank’s portfolio.Keybank National Associationoh reduced its stake in BCR by selling 492 shares or 9.83% in the most recent quarter. The Hedge Fund company now holds 4,512 shares of BCR which is valued at $986,549. C R Bard Inc makes up approx 0.01% of Keybank National Associationoh’s portfolio.Ibm Retirement Fund reduced its stake in BCR by selling 9,327 shares or 51.62% in the most recent quarter. The Hedge Fund company now holds 8,740 shares of BCR which is valued at $1.9 Million. C R Bard Inc makes up approx 0.07% of Ibm Retirement Fund’s portfolio.

C R Bard Inc opened for trading at $220.14 and hit $221.09 on the upside on Friday, eventually ending the session at $219.74, with a gain of 0.53% or 1.16 points. The heightened volatility saw the trading volume jump to 7,59,449 shares. Company has a market cap of $16,111 M.

On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .C R Bard Inc was Initiated by Nomura to “Neutral” on Mar 17, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Leave a Reply

C R Bard Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on C R Bard Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.